The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

Bausch Health Companies Inc.’s years-long process of trying to separate its Bausch + Lomb Corp. eye-care business hit a roadblock Thursday when a potential sale to private equity fell through ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation. In light of Bausch Health's ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX ... increase in IOL power within the central 1.5 mm diameter to slightly extend the depth of focus.